Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

ClinicalTrials.gov ID: NCT04106414

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04106414. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.

Study identification

NCT ID: NCT04106414
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Enrollment: 24 participants

Conditions and interventions

Conditions

Interventions

Nivolumab Drug
BMS- 986205 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 24, 2019 (Actual)
Primary completion: Sep 2027 (Estimated)
Completion: Sep 2027 (Estimated)
Last update posted: Oct 16, 2026

2019 – 2027

United States locations

U.S. sites: 7
U.S. states: 2
U.S. cities: 7

Facility	City	State	ZIP	Site status
Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey	07920	—
Memorial Sloan Kettering Monmouth	Middletown	New Jersey	07748	—
Memorial Sloan Kettering Bergen	Montvale	New Jersey	07645	—
Memorial Sloan Kettering Cancer Center @ Suffolk	Commack	New York	11725	—
Memorial Sloan Kettering Westchester	Harrison	New York	10604	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Memorial Sloan Kettering Nassau	Uniondale	New York	11553	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04106414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 16, 2026 · Synced Nov 14, 2026